{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition&page=48", "query": { "intervention": "Placebo; placebo comparator condition", "page": 48 }, "page_size": 10 }, "pagination": { "page": 48, "page_size": 10, "total_count": 7773, "total_pages": 778, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition&page=49&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition&page=47&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T00:27:15.729Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02370875", "title": "rTMS and Botulinum Toxin in Benign Essential Blepharospasm", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Benign Essential Blepharospasm" ], "interventions": [ { "name": "Magstim RapidStim2", "type": "DEVICE" }, { "name": "Sham Magstim RapidStim2", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "30 Years to 75 Years" }, "enrollment_count": 12, "start_date": "2015-02", "completion_date": "2017-11", "has_results": true, "last_update_posted_date": "2023-09-15", "last_synced_at": "2026-10-17T00:27:15.729Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02370875" }, { "nct_id": "NCT00838981", "title": "Pharmacotherapy & CM for Opioid and Cocaine Dependence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cocaine Dependence" ], "interventions": [ { "name": "Modafinil", "type": "DRUG" }, { "name": "Sugar Pill", "type": "DRUG" }, { "name": "Contingency Management", "type": "BEHAVIORAL" }, { "name": "Methadone", "type": "DRUG" }, { "name": "cognitive behavioral treatment", "type": "BEHAVIORAL" }, { "name": "Voucher Control", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 91, "start_date": "2008-05", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2021-12-03", "last_synced_at": "2026-10-17T00:27:15.729Z", "location_count": 1, "location_summary": "West Haven, Connecticut", "locations": [ { "city": "West Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00838981" }, { "nct_id": "NCT06119581", "title": "A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Neoplasm Metastasis" ], "interventions": [ { "name": "LY3537982", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1264, "start_date": "2023-12-21", "completion_date": "2031-01", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-17T00:27:15.729Z", "location_count": 87, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06119581" }, { "nct_id": "NCT02852967", "title": "A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Plaque Psoriasis" ], "interventions": [ { "name": "Belumosudil", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kadmon Corporation, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 110, "start_date": "2016-09-14", "completion_date": "2019-02-13", "has_results": true, "last_update_posted_date": "2022-03-16", "last_synced_at": "2026-10-17T00:27:15.729Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Irvine, California • Los Angeles, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ocala", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02852967" }, { "nct_id": "NCT04005807", "title": "Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "BPN-14967", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Belite Bio, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2019-07-19", "completion_date": "2019-12-20", "has_results": false, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-10-17T00:27:15.729Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04005807" }, { "nct_id": "NCT05995392", "title": "The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Dry Eye Disease" ], "interventions": [ { "name": "Topical spironolactone ophthalmic solution, 0.005 mg/cc", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Richard W Yee, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-08", "completion_date": "2024-04", "has_results": false, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-10-17T00:27:15.729Z", "location_count": 1, "location_summary": "Bellaire, Texas", "locations": [ { "city": "Bellaire", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05995392" }, { "nct_id": "NCT06031844", "title": "A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Coronary Heart Disease" ], "interventions": [ { "name": "DFV890", "type": "DRUG" }, { "name": "DFV890 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 24, "start_date": "2023-10-16", "completion_date": "2024-12-23", "has_results": true, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-10-17T00:27:15.729Z", "location_count": 6, "location_summary": "Northridge, California • Boca Raton, Florida • Jacksonville, Florida + 3 more", "locations": [ { "city": "Northridge", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Greensboro", "state": "North Carolina" }, { "city": "Rapid City", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06031844" }, { "nct_id": "NCT04421014", "title": "Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults 55 Years Old or Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metabolic Syndrome", "Normal Cognition" ], "interventions": [ { "name": "Ketone Ester drink", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo: isocaloric dextrose drink", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "National Institute on Aging (NIA)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 99, "start_date": "2021-06-24", "completion_date": "2025-06-02", "has_results": true, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-17T00:27:15.729Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04421014" }, { "nct_id": "NCT00446511", "title": "Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Valsartan", "type": "DRUG" }, { "name": "Enalapril", "type": "DRUG" }, { "name": "placebo matched to enalapril", "type": "DRUG" }, { "name": "placebo matched to valsartan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 250, "start_date": "2007-06", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2011-07-12", "last_synced_at": "2026-10-17T00:27:15.729Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00446511" }, { "nct_id": "NCT05132699", "title": "Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Posttraumatic Stress Disorder", "Stress Disorders, Post-Traumatic" ], "interventions": [ { "name": "Cannabidiol (CBD) oral solution", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Massed Prolonged Exposure (mPE)", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 21, "start_date": "2022-04-04", "completion_date": "2023-06-30", "has_results": true, "last_update_posted_date": "2024-10-10", "last_synced_at": "2026-10-17T00:27:15.729Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05132699" } ] }